Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing

MONTREAL, March 04, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies.

“We look forward to initiating the xenograft mice studies as soon as the QA/QC testing is done. Mice studies of this sort provide crucial information and technical guidance for the clinical trials to be conducted in subsequent drug development events,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma

In addition, to working on the development of a treatment for COVID-19 which is now in the transgenic mice testing phase, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC).  Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term.  Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com 
www.sunshinebiopharma.com